

Aggregate Biosciences: Precision Therapeutics for Amyloid Diseases




Team: Molly Jansky, Mark Provost, Linjing Xie, Shandion Santoso
Co-founders: W Vallen Graham, Manija Kazmi, Sharon Blaettler

Advisors: Viktor Ström, Matt Rappaport


Aggregate Biosciences aims to revolutionize the treatment of Alzheimer's and other Amyloid Diseases through precision targeting of amyloid with proprietary technology that exploits structural characteristics of toxic amyloid. With an aging population and lack of effective treatments, Aggregate Biosciences is in a strong position to drive necessary innovation in Amyloid Disease.

Alzheimer's Disease Needs Precision Tools

Current treatments have shown limited effectiveness and lack specificity




Chaperone-Like Amyloid Modulating Proteins (CLAMPs) enable both precision diagnostics and targeted therapy.



Market Opportunity

CAGR of 10%



Total Alzheimer's Therapeutics Market

x 45% US Alzheimer's Therapeutics Market

x 10% conservative estimate of market capture through strategic licensing deals


Secondary Market

Avenues for Growth

- Parkinson's Disease
- Huntington's Disease
- Type 2 Diabetes
- AL Amyloidosis
- AA Amyloidosis
- Hereditary Amyloidosis

Competitive Landscape

Unique Approach in Therapeutics



FDA Approved Alzheimer's Therapeutics

- Lilly**
Kisunla
35% improvement
- Eisai**
- Biogen**
Leqembi
27% improvement